When to Give Ursodeoxycholic Acid (UDCA)
Ursodeoxycholic acid should be given to patients with primary biliary cholangitis (PBC) at a dose of 13-15 mg/kg/day as first-line therapy, but should NOT be used in patients with primary sclerosing cholangitis (PSC). 1
Primary Indications for UDCA
Primary Biliary Cholangitis (PBC) - STRONGLY RECOMMENDED
- All patients with PBC should receive UDCA 13-15 mg/kg/day as the treatment of choice 1
- Start immediately upon diagnosis in patients with:
- Elevated alkaline phosphatase (AP)
- Positive anti-mitochondrial antibodies (AMA ≥1:40) or AMA-M2
- Even if asymptomatic
- Greatest benefit occurs when started in early disease (Stage I-II) before progression to advanced fibrosis or cirrhosis 1
- UDCA improves:
- Serum bilirubin, alkaline phosphatase, gamma-glutamyl transferase
- Histological features and delays disease progression
- Reduces likelihood of liver transplantation or death when started early 1
Gallstone Dissolution - FDA APPROVED
UDCA is indicated for 2:
- Radiolucent, noncalcified gallbladder stones <20 mm in greatest diameter
- Patients who are poor surgical candidates due to:
- Systemic disease
- Advanced age
- High anesthetic risk
- Patient refusal of surgery
- Dose: 8-10 mg/kg/day for up to 24 months
- Expected dissolution rate: ~30% in unselected patients; up to 81% for stones ≤5 mm 2
Gallstone Prevention After Bariatric Surgery - RECOMMENDED
- Give UDCA 250-600 mg daily for 6 months after laparoscopic sleeve gastrectomy or gastric bypass 3, 4, 5
- Significantly reduces:
- Cholecystectomy rates (8.3% vs 13.9%)
- ERCP requirements (0.3% vs 2.5%)
- Overall gallstone disease requiring intervention (8.9% vs 15.8%) 3
- Number needed to treat to prevent one cholecystectomy: approximately 10 5
- This aligns with American Society for Metabolic and Bariatric Surgery 2019 guidelines 3
Intrahepatic Cholestasis of Pregnancy (ICP) - CONDITIONALLY RECOMMENDED
- UDCA 10-15 mg/kg/day (typically 300 mg 2-3 times daily or 500 mg twice daily) for bile acid levels ≥10 μmol/L 6
- Primary benefit: maternal pruritus relief (usually within 1-2 weeks)
- Perinatal outcome benefit is uncertain based on recent large RCT, but may reduce preterm births 6
- Can titrate to maximum 21 mg/kg/day if pruritus persists
- Well-tolerated; mild nausea/dizziness in up to 25% of patients 6
When NOT to Give UDCA
Primary Sclerosing Cholangitis (PSC) - STRONGLY CONTRAINDICATED
- Do NOT use UDCA as medical therapy for adult PSC patients 7
- Evidence shows:
- No improvement in clinical outcomes (death, transplantation, histologic progression) 7
- High-dose UDCA (28-30 mg/kg/day) may be HARMFUL - associated with increased risk of death, liver transplantation, and variceal development 1, 8
- Low-to-moderate doses improve biochemistry but not mortality or morbidity 8
- Exception: Consider in PSC/autoimmune hepatitis overlap syndrome, but use corticosteroids as primary therapy 7
Other Contraindications
- Calcified gallstones (UDCA ineffective) 2
- Gallstones >20 mm (poor dissolution rates) 2
- Complete biliary obstruction
- Acute cholecystitis or cholangitis
Dosing Summary by Indication
| Indication | Dose | Duration | Strength of Recommendation |
|---|---|---|---|
| PBC | 13-15 mg/kg/day | Indefinite | STRONG [1] |
| PSC | DO NOT USE | N/A | STRONG AGAINST [7,8] |
| Gallstone dissolution | 8-10 mg/kg/day | Up to 24 months | Moderate [2] |
| Post-bariatric surgery | 250-600 mg/day | 6 months | Strong [3,4,5] |
| ICP | 10-15 mg/kg/day | Until delivery | Moderate [6] |
Critical Pitfalls to Avoid
- Do not use UDCA in PSC - this is the most important contraindication, as high doses may worsen outcomes 8
- Do not delay UDCA in PBC - early treatment (Stage I-II) provides maximum benefit for mortality/transplantation reduction 1
- Do not use UDCA for calcified or large (>20 mm) gallstones - dissolution rates are negligible 2
- Monitor biochemical response in PBC at 12 months - inadequate response should prompt consideration of second-line agents 9, 10
- Cost and compliance barriers - 45% of patients cite cost as barrier to adherence after bariatric surgery 3